Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes

References

• . Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371(9626):1800–1809
   PubMed Web of Science ®Google Scholar
• . Seshasai SR, Kaptoge S, Thompson A, ; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–841
   PubMed Web of Science ®Google Scholar
• . Hemmingsen B, Lund SS, Gluud C, . Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898
   PubMed Web of Science ®Google Scholar
• . Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs. 2003;63(12):1165–1184
   PubMedGoogle Scholar
• . Niswender K. Diabetes and obesity: therapeutic targeting and risk reduction—a complex interplay. Diabetes Obes Metab. 2010;12(4):267–287
   PubMedGoogle Scholar
• . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Macfarlane DP, Paterson KR, Fisher M. Oral antidiabetic agents as cardiovascular drugs. Diabetes Obes Metab. 2007;9(1):23–30
   PubMedGoogle Scholar
• . Zarich SW. Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nat Rev Endocrinol. 2009;5(9):500–506
   PubMedGoogle Scholar
• . Ovalle F. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clin Ther. 2011;33(4):393–407
   PubMed Web of Science ®Google Scholar
• . Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vase Pharmacol. 2010;8(3):327–337
   PubMed Web of Science ®Google Scholar
• . Boussageon R, Supper I, Bejan-Angoulvant T, . Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9(4):e1001204
   PubMed Web of Science ®Google Scholar
• . Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes [published online ahead of print March 22, 2013]. Diabetes Metab
   Google Scholar
• . Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012;13(1):81–99
   PubMed Web of Science ®Google Scholar
• . Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(4):489–512
   PubMedGoogle Scholar
• . Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010;70(16):2089–2112
   PubMed Web of Science ®Google Scholar
• . He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012;51(3):147–162
   PubMed Web of Science ®Google Scholar
• . Yang LP. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs. 2012;72(2):229–248
   PubMed Web of Science ®Google Scholar
• . Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs. 2011;71(5):611–624
   PubMedGoogle Scholar
• . Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(15):2051–2072
   PubMedGoogle Scholar
• . Rendell M, Drincic A, Andukuri R. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012;13(4):553–563
   PubMed Web of Science ®Google Scholar
• . Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012;38(2):89–101
   PubMed Web of Science ®Google Scholar
• . Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410–1418
   PubMed Web of Science ®Google Scholar
• . Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis [published online ahead of print April 20, 2012]. Diabetes Obes Metab
   Google Scholar
• . Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med. 2010;122(3):71–80
   PubMed Web of Science ®Google Scholar
• . Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab. 2012;14(9):810–820
   PubMed Web of Science ®Google Scholar
• . Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245–254
   PubMed Web of Science ®Google Scholar
• . Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30(12):1127–1142
   PubMed Web of Science ®Google Scholar
• . Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf. 2009;8(5):573–584
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, ; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187–215
   PubMed Web of Science ®Google Scholar
• . Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009;157(8):1340–1351
   PubMed Web of Science ®Google Scholar
• . Mudaliar S, Henry RR. The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia. 2012;55(7):1865–1868
   PubMedGoogle Scholar
• . Murohara T. Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection. J Am Coll Cardiol. 2012;59(3):277–279
   PubMedGoogle Scholar
• . Ban K, Hui S, Drucker DJ, Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens. 2009;3(4):245–259
   PubMed Web of Science ®Google Scholar
• . Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol. 2012;109(11):1681–1685
   PubMedGoogle Scholar
• . Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vase Dis Res. 2012;9(2):109–116
   PubMed Web of Science ®Google Scholar
• . Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol. 2013;10(2):73–84
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705
   PubMed Web of Science ®Google Scholar
• . Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med. 2011;123(6):189–201
   PubMed Web of Science ®Google Scholar
• . Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009;18(10):1495–1503
   PubMed Web of Science ®Google Scholar
• . Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46(11):1453–1469
   PubMedGoogle Scholar
• . Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27(4):362–372
   PubMed Web of Science ®Google Scholar
• . Esposito K, Cozzolino D, Bellastella G, . Dipeptidyl peptidase-4 inhibitors and HbA1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011;13(7):594–603
   PubMed Web of Science ®Google Scholar
• . Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224–235
   PubMed Web of Science ®Google Scholar
• . Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86(1):44–57
   PubMed Web of Science ®Google Scholar
• . Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26(7):540–549
   PubMed Web of Science ®Google Scholar
• . Gross JL, Rogers J, Polhamus D, . A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus. BMJ Open. 2013;3(3):e001844
   Google Scholar
• . Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470–512
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Schweizer A, Rosenstock J, . Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab. 2008;10(10):931–938
   PubMed Web of Science ®Google Scholar
• . Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011;71(11):1441–1467
   PubMed Web of Science ®Google Scholar
• . O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100(5):899–904
   PubMed Web of Science ®Google Scholar
• . Barbieri M, Rizzo MR, Marfella R, . Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013;227(2):349–354
   PubMed Web of Science ®Google Scholar
• . Ross SA, Dzida G, Vora J, Khunti K, Kaiser M, Ligthelm RJ. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin. 2011;27(7):1431–1438
   PubMed Web of Science ®Google Scholar
• . Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int J Clin Pract Suppl. 2007;154:19–28
   PubMedGoogle Scholar
• . Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786):182–197
   PubMed Web of Science ®Google Scholar
• . Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin. 2007;23(7):1493–1507
   PubMed Web of Science ®Google Scholar
• . Waters SB, Topp BG, Siler SQ, Alexander CM. Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J Diabetes Sci Technol. 2009;3(1):68–82
   PubMedGoogle Scholar
• . Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vase Health Risk Manag. 2010;6:541–548
   PubMedGoogle Scholar
• . Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33(8):1759–1765
   PubMed Web of Science ®Google Scholar
• . Wang B, Ni Y, Zhong J, Sun F. Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension. J Diabetes. 2012;4(1):22–29
   PubMedGoogle Scholar
• . Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. J Am Soc Hypertens. 2012;6(3):163–168
   PubMedGoogle Scholar
• . Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56(4):728–733
   PubMed Web of Science ®Google Scholar
• . Mistry GC, Maes AL, Lasseter KC, . Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5):592–598
   PubMed Web of Science ®Google Scholar
• . Jackson EK. Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome. Hypertension. 2010;56(4):581–583
   PubMedGoogle Scholar
• . Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112–120
   PubMed Web of Science ®Google Scholar
• . Ogawa S, Ishiki M, Nako K, . Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223(2):133–135
   PubMedGoogle Scholar
• . Tanaka T, Nangaku M, Nishiyama A. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. Curr Opin Nephrol Hypertens. 2011;20(5):476–481
   PubMedGoogle Scholar
• . Chaudhuri A, Dandona P. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes Obes Metab. 2011;13(10):869–879
   PubMedGoogle Scholar
• . Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U. S. Food and Drug Administration. N Engl J Med. 2010;363(16):1489–1491
   PubMed Web of Science ®Google Scholar
• . Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol. 2011;10:61
   PubMed Web of Science ®Google Scholar
• . Xiao C, Dash S, Lewis GF. Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system. Cardiovasc Hematol Agents Med Chem. 2012;10(4):289–294
   PubMedGoogle Scholar
• . Farr S, Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol. 2012;23(1):56–61
   PubMed Web of Science ®Google Scholar
• . Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):366–373
   PubMed Web of Science ®Google Scholar
• . Matikainen N, Mänttäri S, Schweizer A, . Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49(9):2049–2057
   PubMed Web of Science ®Google Scholar
• . Matikainen N, Taskinen MR. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes [published online ahead of print December 8, 2012]. Diabet Med
   Google Scholar
• . Boschmann M, Engeli S, Dobberstein K, . Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin EndocrinolMefaft. 2009;94(3):846–852
   PubMed Web of Science ®Google Scholar
• . Noda Y, Miyoshi T, Oe H, . Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol. 2013;12(1):8
   PubMedGoogle Scholar
• . Eliasson B, Möller-Goede D, Eeg-Olofsson K, . Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55(4):915–925
   PubMedGoogle Scholar
• . Derosa G, Ragonesi PD, Fogari E, . Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation [published online ahead of print September 11, 2012]. Fundam Clin Pharmacol
   Google Scholar
• . Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29(1):14–25
   PubMedGoogle Scholar
• . Derosa G, Maffioli P, Salvadeo SA, . Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism. 2010;59(6):887–895
   PubMed Web of Science ®Google Scholar
• . Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58(1):69–73
   PubMed Web of Science ®Google Scholar
• . Satoh-Asahara N, Sasaki Y, Wada H, . A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013;62(3):347–351
   PubMed Web of Science ®Google Scholar
• . Makdissi A, Ghanim H, Vora M, . Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab. 2012;97(9):3333–3341
   PubMed Web of Science ®Google Scholar
• . Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076–2082
   PubMed Web of Science ®Google Scholar
• . Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an “endothelial resistance” to glucagon-like peptide 1 in diabetes. Diabetes Care. 2011;34(3):697–702
   PubMed Web of Science ®Google Scholar
• . Koren S, Shemesh-Bar L, Tirosh A, . The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012;14(7):561–567
   PubMedGoogle Scholar
• . Motta AJ, Koska J, Reaven P, Migrino RQ. Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity. Recent Pat Cardiovasc Drug Discov. 2012;7(1):2–9
   PubMedGoogle Scholar
• . Koska J. Incretins and preservation of endothelial function. Cardiovasc Hematol Agents Med Chem. 2012;10(4):295–308
   PubMedGoogle Scholar
• . Nyström T, Gutniak MK, Zhang Q, . Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209–E1215
   PubMed Web of Science ®Google Scholar
• . Mannucci E, Dicembrini I. Incretin-based therapies and cardiovascular risk. Curr Med Res Opin. 2012;28(5):715–721
   PubMed Web of Science ®Google Scholar
• . van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–2077
   PubMed Web of Science ®Google Scholar
• . Kubota Y, Miyamoto M, Takagi G, . The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J. Korean Med. Sci. 2012;27(11):1364–1370
   PubMed Web of Science ®Google Scholar
• . Matsubara J, Sugiyama S, Akiyama E, . Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77(5):1337–1344
   PubMed Web of Science ®Google Scholar
• . Fadini GP, Boscaro E, Albiero M, . The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1 alpha. Diabetes Care. 2010;33(7):1607–1609
   PubMed Web of Science ®Google Scholar
• . Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011;55(1–3):10–16
   PubMed Web of Science ®Google Scholar
• . YhHb L, Rw S, Ae D. GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells [published online ahead of print November 28, 2012]. Mol Biol Rep
   Google Scholar
• . Gupta AK, Verma AK, Kailashiya J, Singh SK, Kumar N. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets. 2012;23(8):565–570
   PubMed Web of Science ®Google Scholar
• . Khan S, Khan S, Imran M, Pillai KK, Akhtar M, Najmi AK. Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus—targeting thrombogenesis [published online ahead of print January 28, 2013]. Expert Opin Ther Targets
   Google Scholar
• . Matsubara J, Sugiyama S, Sugamura K, . A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012;59(3):265–276
   PubMedGoogle Scholar
• . Matheeussen V, Jungraithmayr W, De Meester I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol Ther. 2012;136(3):267–282
   PubMedGoogle Scholar
• . Rahmi RM, Uchida AH, Rezende PC, . Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease [published online ahead of print December 18, 2012]. Diabetes Care
   Google Scholar
• . Hage C, Brismar K, Efendic S, Lundman P, Ryden L, Mellbin L. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities—the BEGAMI study. J Intern Med. 2013;273(4):410–421
   PubMed Web of Science ®Google Scholar
• . Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3(2):195–201
   PubMed Web of Science ®Google Scholar
• . Post S, van den Broek AJ, Rensing BJ, Pasterkamp G, Goumans MJ, Doevendans PA. Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: insights from the REPERATOR study. J Mol Cell Cardiol. 2012;53(6)899–905
   PubMedGoogle Scholar
• . Theiss HD, Brenner C, Engelmann MG, . Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)—rationale, design and first interim analysis. Int J Cardiol. 2010;145(2):282–284
   PubMedGoogle Scholar
• . Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med. 2008;359(11):1092–1095
   PubMedGoogle Scholar
• . Anagnostis P, Athyros VG, Adamidou F, . Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13(4):302–312
   PubMed Web of Science ®Google Scholar
• . Green JB. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety. Postgrad Med. 2012;124(4):54–61
   PubMed Web of Science ®Google Scholar
• . Williams-Herman D, Engel SS, Round E, . Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485–494
   PubMed Web of Science ®Google Scholar
• . Frederich R, Alexander JH, Fiedorek FT, . A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27
   PubMed Web of Science ®Google Scholar
• . Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6
   PubMed Web of Science ®Google Scholar
• . White WB, Pratley R, Fleck P, . Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus [published online ahead of print March 12, 2013]. Diabetes Obes Metab
   Google Scholar
• . Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3
   PubMed Web of Science ®Google Scholar
• . Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;2:CD006739
   Google Scholar
• . Fonseca VA. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am J Cardiol. 2011;108( 3 Suppl):52B–58B
   PubMed Web of Science ®Google Scholar
• . Bethel M, Green J, Califf R, Holman RR. Rationale and design of the trial evaluating cardiovascular outcomes with sitagliptin (TECOS) [abstract]. Diabetes. 2009;59( suppl 1):A555
   Google Scholar
• . Scirica BM, Bhatt DL, Braunwald E, . The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus–thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011;162(5):818–825.e6
   PubMed Web of Science ®Google Scholar
• . White WB, Bakris GL, Bergenstal RM, . Examination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162(4):620–626.e1
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Marx N, Kahn SE, . Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial [published online ahead of print February 28, 2013]. Diab Vase Dis Res
   Google Scholar
• . Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12(1):3
   PubMedGoogle Scholar
• . Gallwitz B, Rosenstock J, Rauch T, . 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475–483
   PubMed Web of Science ®Google Scholar
• . Patil HR, Al Badarin FJ, Al Shami HA, . Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826–833
   PubMed Web of Science ®Google Scholar